Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Arpida AG

Home Clinical Trial Sponsors and OrganizationsArpida AG

Arpida AG

ACTIVE

Switzerlandwww.arpida.comPrivate11–50 employeesEstablished: 1997-01-01

Part of Evolva Holding SA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

11

8 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1997

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

2

18.2%

Phase 1

1

9.1%

Phase 2

1

9.1%

Trial Status Distribution

Active, not recruiting

8

72.7%

Completed

2

18.2%

Terminated

1

9.1%

Clinical Trials

Trials sponsored by this organization (11)

Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia

Nov 2007135 participants

Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia suspected or confirmed to be due to Gram-positive pathogens

Active, not recruiting

Aug 2007135 participants

Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia suspected or confirmed to be due to Gram-positive pathogens

Active, not recruiting

Jul 2007135 participants

Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia suspected or confirmed to be due to Gram-positive pathogens

Active, not recruiting

Jul 2007135 participants

Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections - Arpida’s Skin and Skin structure Infection STudy-2 (ASSIST-2)

Active, not recruiting

Dec 2006500 participants

Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus intravenous linezolid in complicated skin and skin structure infections - ASSIST-2

Active, not recruiting

Mar 2006500 participants

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus intravenous linezolid in complicated skin and skinstructure infections - ASSIST-2

Active, not recruiting

Jan 2006500 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials11
Approvals
News

Back to Organizations